ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. Microbot Medical's annualized return on capital (ROC %) for the quarter that ended in Mar. 2026 was -527.82%.
As of today (2026-07-01), Microbot Medical's WACC % is 9.03%. Microbot Medical's ROC % is -939.45% (calculated using TTM income statement data).
Microbot Medical earns returns that do not match up to its cost of capital. It will destroy value as it grows.
Microbot Medical (FRA:CY9D) ROC % Explanation
ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.
There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.
Why is ROC % important?
Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.
As of today, Microbot Medical's WACC % is 9.03%. Microbot Medical's ROC % is -939.45% (calculated using TTM income statement data).
Microbot Medical earns returns that do not match up to its cost of capital. It will destroy value as it grows.
Be Aware
Like ROE % and ROA %, ROC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Microbot Medical ROC % Related Terms
Microbot Medical ROC % Historical Data
* Premium members only.
The historical data trend for Microbot Medical's ROC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note:
The Operating Income data used here is four times the quarterly (Mar. 2026) data.
The tax rate is limited to between 0% and 100%.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Microbot Medical (FRA:CY9D) has a ROC % of -527.82% as of Mar. 2026. Return on capital is the ratio of current-period net income to average two-period capital. View historical data on Microbot Medical and its competitors.
Is Microbot Medical's ROC % too high?
Microbot Medical's current ROC % is -527.82%. Overall, Microbot Medical has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Microbot Medical's ROC % compare to STXS and POCI?
Microbot Medical's ROC % of -527.82% can be compared against companies in the Medical Devices & Instruments industry. The industry median ROC % is 1.25. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC % for a Medical Devices & Instruments company?
The median ROC % among Medical Devices & Instruments companies is 1.25, based on 847 companies in the industry. Companies in the top quartile (top 25%) have a ROC % significantly above this median, while those in the bottom quartile fall well below. However, ROC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC % mean?
A high ROC % can signal that a stock is expensive relative to its fundamentals. Return on capital is the ratio of current-period net income to average two-period capital. View historical data on Microbot Medical and its competitors. For the Medical Devices & Instruments industry, the median ROC % is 1.25 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Microbot Medical's current ROC % is -527.82%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Microbot Medical stock overvalued right now?
Microbot Medical (FRA:CY9D) has a current ROC % of -527.82%. The current ROC % is -527.82%. Microbot Medical's overall GF Score™ is 32/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC % calculated?
ROC % is calculated from a company's financial statements. For Microbot Medical (FRA:CY9D), the current ROC % is -527.82% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Microbot Medical Inc is a medical device company specializing in the research, design, and development of next-generation robotic endoluminal surgery devices targeting the minimally invasive surgery space. Using its LIBERTY technological platform, the company has developed the LIBERTY Endovascular Robotic Surgical System, a fully disposable robot for various endovascular interventional procedures. The company has a single operating and reportable segment, which is the development of robotic devices for endoluminal surgery.
32GF Score
Get the complete analysis for FRA:CY9D
ROC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:CY9D has been successfully added to your 
